Declaration of Voting Results & Voting Rights Announcements • Nov 14, 2018
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Regulated information
Brussels, Belgium, 14 November 2018, 5.45 pm (CEST) – ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 13 November, 2018, the result of which is - following a capital increase completed on November 8 th – that Rodolphe de Spoelberch have now 9,90% of the Company's voting rights, and has thus decreased its stake below the 10% threshold.
The statement dated 13 November 2018 notably includes the following information:
Passive crossing of a threshold
A person who notifies alone
• Person subject to the notification requirement
Rodolphe de Spoelberch – Rue Joseph Stallaert 20, 1050 Bruxelles
November 8 th , 2018
• Threshold crossed (%)
Downward crossing of the 10% threshold
• Denominator
A total of 18,054,347 voting rights
• This notification is available on ASIT biotech's website, in the Documentation / Regulated information section:
https://www.asitbiotech.com/investors/documentation
***
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.
ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at www.asitbiotech.com.
Company Thierry Legon, CEO ASIT biotech Tel.: +32 2 264 03 90
Media and Investor Relations - France NewCap Dusan Oresansky / Pierre Laurent Tel.: +33 1 44 71 94 92 [email protected]
Media Relations - Belgium
Laure-Eve Monfort Tel.: +32 2 290 90 93 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.